Fine tuning of the innate and adaptive immune responses by Interleukin-2

Fine tuning of the innate and adaptive immune responses by Interleukin-2

Novel immunotherapies for cancer and other diseases aim to trigger the immune system to produce durable responses, while overcoming the immunosuppression that may contribute to disease severity, and in parallel considering immunosafety aspects. Interleukin-2 (IL-2) was one of the first cytokines tha...

Full description

Saved in:

Bibliographic Details
Main Authors:	Christina Sakellariou, Luise A. Roser, Susanne Schiffmann, Malin Lindstedt
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Journal of Immunotoxicology
Subjects:	Interleukin-2 dendritic cells T cells immunotherapy cancer adverse events
Online Access:	https://www.tandfonline.com/doi/10.1080/1547691X.2024.2332175
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept
by: Luise A. Roser, et al.
Published: (2024-12-01)

Revival of recombinant IL-2 therapy – approaches from the past until today
by: Luise A. Roser, et al.
Published: (2024-12-01)

Open-Label Clinical Trial on the Impact of Autologous Dendritic Cell Therapy on Albuminuria and Inflammatory Biomarkers (Interleukin-6, Interleukin-10, Tumor Necrosis Factor α) in Diabetic Kidney Disease (DKD)
by: Jonny, et al.
Published: (2024-12-01)

Current state and prospects of using dendritic cell vaccination for cancer immunotherapy
by: I.Yu. Filin, et al.
Published: (2022-09-01)

Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory‐wide cohort study
by: Stephen Lam Chan, et al.
Published: (2020-10-01)

Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade
by: Daniel A. Ruiz-Torres, et al.
Published: (2024-12-01)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
by: Alisa Lepper, et al.
Published: (2023-12-01)

Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses
by: Heidi Harjunpää, et al.
Published: (2024-12-01)

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
by: Renata Pacholczak-Madej, et al.
Published: (2024-11-01)

Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials
by: Wendi Jiang, et al.
Published: (2024-12-01)

The Effect of Autologous Dendritic Cell Immunotherapy on Kidney Function and Endothelial Dysfunction of Patients with Diabetic Kidney Disease (DKD): An Open Label Clinical Trial
by: Martina Lily Yana, et al.
Published: (2025-01-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
by: Spencer G. Van Decar, et al.
Published: (2024-01-01)

Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab
by: Jared Weiss, et al.
Published: (2024-12-01)

The role of interleukin-17 in inflammation-related cancers
by: Xingru Zhang, et al.
Published: (2025-01-01)

A Chemically Defined TLR3 Agonist with Anticancer Activity
by: Julie Le Naour, et al.
Published: (2023-12-01)

Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways
by: Alexander Mazein, et al.
Published: (2024-12-01)

Innate immune cells in vascular lesions: mechanism and significance of diversified immune regulation
by: Jinjing Wu, et al.
Published: (2025-12-01)

Predictive value of dendritic cell-related genes for prognosis and immunotherapy response in lung adenocarcinoma
by: Zihao Sun, et al.
Published: (2025-01-01)

An in vitro investigation into the cytotoxic impact of antigen-presenting dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells
by: Shengnan Yang, et al.
Published: (2024-11-01)

Association of vitiligo with immune-checkpoint inhibitor therapy: A systematic review
by: Lauren Fleshner, MSc, et al.
Published: (2025-02-01)

Multiparameter Flow Cytometric Analysis of the Conventional and Monocyte-Derived DC Compartment in the Murine Spleen
by: Ronald A. Backer, et al.
Published: (2024-11-01)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01)

Prognostic Factors for Patients with Small-Cell Lung Cancer Treated with Chemoimmunotherapy: A Retrospective Multicenter Study
by: Takashi Hatori, et al.
Published: (2024-10-01)

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
by: I.A.J. van Duin, et al.
Published: (2024-12-01)

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
by: Paul G. Pavicic, et al.
Published: (2023-12-01)

Enhancing adoptive T‐cell therapy with fucoidan‐based IL‐2 delivery microcapsules
by: Eun Young Jeon, et al.
Published: (2023-01-01)

Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity
by: Steven Brem
Published: (2024-12-01)

Phenotypic insights into genetic risk factors for immune-related adverse events in cancer immunotherapy
by: Haochuan Ma, et al.
Published: (2024-11-01)

Serum interleukin-6, interleukin-8, and interleukin-1 receptor antagonist levels in South Indian fibromyalgia patients and its correlation with disease severity
by: Sandeep Surendran, et al.
Published: (2021-01-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

CD4+ T Cells Mediate Dendritic Cell Licensing to Promote Multi‐Antigen Anti‐Leukemic Immune Response
by: Luis Gil‐de‐Gómez, et al.
Published: (2025-01-01)

The role of interleukin-6 classic and trans-signaling and interleukin-11 classic signaling in gastric cancer cells
by: Josephine Runge, et al.
Published: (2024-08-01)

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
by: Lin Zhu, et al.
Published: (2024-12-01)

Editorial: Tumor microenvironment and beyond: imaging systemic immunity with PET
by: Jelena Levi, et al.
Published: (2024-12-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases
by: Shih-Wen Huang, et al.
Published: (2025-01-01)

Full-length and N-terminally truncated recombinant interleukin-38 variants are similarly inefficient in antagonizing interleukin-36 and interleukin-1 receptors
by: Alejandro Diaz-Barreiro, et al.
Published: (2025-01-01)

Exploratory Research for HIF-1α Overexpression Tumor Antigen in the Activation of Dendritic Cells and the Potent Anti-Tumor Immune Response
by: Zhao J, et al.
Published: (2024-12-01)

Single-cell RNA-seq reveals immune cell heterogeneity and increased Th17 cells in human fibrotic skin diseases
by: Cheng-Cheng Deng, et al.
Published: (2025-01-01)